C
Catherine Sebban
Researcher at University of Lyon
Publications - 22
Citations - 2825
Catherine Sebban is an academic researcher from University of Lyon. The author has contributed to research in topics: Autologous stem-cell transplantation & Rituximab. The author has an hindex of 13, co-authored 22 publications receiving 2371 citations.
Papers
More filters
Journal ArticleDOI
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier,Catherine Thieblemont,Eric Van Den Neste,Gérard Lepeu,Isabelle Plantier,Sylvie Castaigne,Sophie Lefort,Gerald Marit,Margaret Macro,Catherine Sebban,Karim Belhadj,Dominique Bordessoule,Christophe Fermé,Hervé Tilly +13 more
TL;DR: The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP and underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.
Journal ArticleDOI
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc André,Theodore Girinsky,Massimo Federico,Oumedaly Reman,Catherine Fortpied,Manuel Gotti,Olivier Casasnovas,Pauline Brice,Richard W.M. van der Maazen,Alessandro Re,Veronique Edeline,Christophe Fermé,Gustaaf W. van Imhoff,Francesco Merli,Reda Bouabdallah,Catherine Sebban,Lena Specht,Aspasia Stamatoullas,Richard Delarue,Valeria Fiaccadori,Monica Bellei,Tiana Raveloarivahy,Annibale Versari,Martin Hutchings,Michel Meignan,John M. M. Raemaekers +25 more
TL;DR: In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation when ePET is positive, and switching to BEACOPPesc + INRT significantly improved 5-year PFS.
Journal ArticleDOI
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles,Nicolas Mounier,Sophie de Guibert,Franck Morschhauser,Chantal Doyen,Jean-François Rossi,Corinne Haioun,Pauline Brice,Beatrice Mahe,Reda Bouabdallah,Bruno Audhuy,Christophe Fermé,Caroline Dartigeas,Pierre Feugier,Catherine Sebban,Luc Xerri,Charles Foussard +16 more
TL;DR: With a 5-year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy.
Journal ArticleDOI
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine,Olivier Hermine,Eva Hoster,Jan Walewski,André Bosly,Stephan Stilgenbauer,Catherine Thieblemont,Michal Szymczyk,Reda Bouabdallah,Michael Kneba,Michael Hallek,Gilles Salles,Pierre Feugier,Vincent Ribrag,Josef Birkmann,Roswitha Forstpointner,Corinne Haioun,Mathias Hänel,Rene-Olivier Casasnovas,Jürgen Finke,Norma Peter,Kamal Bouabdallah,Catherine Sebban,Thomas Fischer,Ulrich Dührsen,Bernd Metzner,Georg Maschmeyer,Lothar Kanz,Christian Schmidt,Richard Delarue,Nicole Brousse,Wolfram Klapper,Elizabeth Macintyre,Marie-Hélène Delfau-Larue,Christiane Pott,Wolfgang Hiddemann,Michael Unterhalt,Martin Dreyling +37 more
TL;DR: Investigating whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome found it should be considered standard of care in patients aged 65 years or younger with mantle cell lymphoma.
Journal ArticleDOI
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban,Nicolas Mounier,Nicole Brousse,Coralie Belanger,Pauline Brice,Corinne Haioun,Hervé Tilly,Pierre Feugier,Reclah Bouabdallah,Chantal Doyen,Gilles Salles,Bertrand Coiffier +11 more
TL;DR: After long-term follow-up, the study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma and high- dose therapy should be reserved for relapsing patients.